Natera, Inc. (NASDAQ: NTRA) said its shares go south after it announced that new data on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, will be presented at the 2022 ASCO® Annual Meeting taking place this weekend.
There will be seven poster presentations and one oral presentation highlighting the prognostic and predictive value of its personalized MRD technology in a wide range of tumors. These data further support Signatera as an effective tool for MRD detection and treatment response monitoring.
In one study, 188 patients with primary breast cancer of different molecular subtypes were followed post-surgery and adjuvant therapy for up to 12 years as part of the prospective, multi-center EBLIS study.
Serial Signatera testing predicted metastatic relapse with a median lead interval of 10 months (range: 0-39 months) and relapse detection of 88% (30/34 patients). Relapse-free and overall survival was significantly poorer in patients who were Signatera positive, regardless of subtype (HR 52.98 and 53.69, respectively).
In another study, 17 patients with non-resectable stage I-III NSCLC were monitored before, during and after radiotherapy with or without concurrent systemic therapy and adjuvant durvalumab, for a median of 26 months. ctDNA was detected in 82% (14/17) of patients pre-treatment. 100% (9/9) of cases where clinical recurrence occurred had detectable ctDNA, a median of 5.4 months ahead of radiological relapse. ctDNA status after radiotherapy (single time point) as well as during systemic therapy (longitudinally) was highly predictive of disease recurrence.
NTRA shares dispensed $1.56, or 3.8%, to $39.63
Related Stories
